Regístrese ahora para una mejor cotización personalizada!

FDA grants 23andMe clearance to offer interpretive drug information

18 de agosto de 2023 Hi-network.com

The US Food and Drug Administration (FDA) granted 23andMe a 510(k) clearance that allows the company to offer a pharmacogenetics report on two medications: clopidogrel (prescribed for certain heart conditions) and citalopram (a depression medication). With the new clearance, 23andMe can provide interpretive drug information to customers for two medications without a confirmatory testing. 23andMe Chief Legal and Regulatory Officer Kathy Hibbs said that the clearance is a testament to the clinical validity of 23andMe results. In the decision, the FDA stated that the 23andMe pharmacogenetic report is a safe and effective consumer product that can support customers with certain genotypes to understand how their body may respond to certain medications and encourage conversations with their healthcare provider. 

 

tag-icon Etiquetas calientes: Digital Health: Technology applications (en inglés)

Copyright © 2014-2024 Hi-Network.com | HAILIAN TECHNOLOGY CO., LIMITED | All Rights Reserved.